Alvotech (ALVO) News Today $8.32 +0.12 (+1.46%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$8.25 -0.07 (-0.79%) As of 10/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period A Fresh Look at Alvotech (NasdaqGM:ALVO) Valuation After Recent Stock UptickOctober 3 at 12:59 PM | finance.yahoo.comEMA Greenlights for Key Biosimilars Might Change the Case for Investing in Alvotech (ALVO)October 2 at 4:43 PM | finance.yahoo.comAlvotech (NASDAQ:ALVO) Raised to "Buy" at Deutsche Bank AktiengesellschaftSeptember 25, 2025 | americanbankingnews.comAlvotech (NASDAQ:ALVO) Shares Gap Up After Analyst UpgradeSeptember 24, 2025 | americanbankingnews.comAlvotech upgraded to “buy” by Deutsche Bank as biosimilar launches boost outlookSeptember 24, 2025 | investing.comAlvotech jumps as Deutsche Bank lifts to Buy on ’material thematic opportunity’September 23, 2025 | investing.comAlvotech rises 12.9%September 23, 2025 | msn.comAlvotech (NASDAQ:ALVO) Shares Gap Up Following Analyst UpgradeSeptember 23, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Upgraded to Buy at Deutsche Bank AktiengesellschaftSeptember 23, 2025 | marketbeat.comAlvotech says CHMP adopts positive opinion for AVT03September 22, 2025 | msn.comEuropean Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®September 22, 2025 | markets.businessinsider.comEuropean Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization PartnerSeptember 22, 2025 | markets.businessinsider.comAlvotech Gains Key Approvals for Biosimilars in Japan and EuropeSeptember 22, 2025 | tipranks.comEuropean Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®September 22, 2025 | globenewswire.comEuropean Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®September 22, 2025 | globenewswire.comAlvotech and Advanz Pharma Announce Positive CHMP Opinion for Gobivaz® Biosimilar in EuropeSeptember 22, 2025 | quiverquant.comQAlvotech and Advanz Pharma Announce Positive EMA Opinion for Gobivaz®, a Biosimilar to Simponi®September 22, 2025 | quiverquant.comQEuropean Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization PartnerSeptember 22, 2025 | globenewswire.comEuropean Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization PartnerSeptember 22, 2025 | globenewswire.comAlvotech announces marketing approval in Japan for three biosimilarsSeptember 20, 2025 | msn.comAlvotech gets marketing approval in Japan for three new biosimilarsSeptember 19, 2025 | seekingalpha.comAlvotech and Fuji Pharma Receive Approval for Three New Biosimilars in JapanSeptember 19, 2025 | quiverquant.comQAlvotech and Fuji Pharma Announce Marketing Approval for Three New Biosimilars in JapanSeptember 19, 2025 | quiverquant.comQAlvotech Announces Marketing Approval in Japan of Three New BiosimilarsSeptember 19, 2025 | globenewswire.comAlvotech Announces Marketing Approval in Japan of Three New BiosimilarsSeptember 19, 2025 | globenewswire.comAlvotech (NASDAQ:ALVO) Sees Large Drop in Short InterestSeptember 17, 2025 | marketbeat.comAlvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comPointState Capital LP Cuts Stake in Alvotech $ALVOSeptember 8, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Short Interest UpdateSeptember 8, 2025 | marketbeat.comAlvotech to Present at Morgan Stanley 23rd Annual Global Healthcare Conference in New YorkSeptember 4, 2025 | quiverquant.comQAlvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New YorkSeptember 4, 2025 | globenewswire.comAlvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New YorkSeptember 4, 2025 | globenewswire.comAlvotech $ALVO Shares Sold by Sculptor Capital LPSeptember 1, 2025 | marketbeat.comVanguard Group Inc. Purchases 995,538 Shares of Alvotech $ALVOAugust 29, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Sees Large Volume Increase - What's Next?August 27, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Is Posting Healthy Earnings, But It Is Not All Good NewsAugust 25, 2025 | uk.finance.yahoo.comAlvotech (NASDAQ:ALVO) Downgraded to "Hold" Rating by Zacks ResearchAugust 22, 2025 | marketbeat.comAlvotech, Advanz Pharma get EU nod for Eylea biosimilarAugust 21, 2025 | seekingalpha.comAdvanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®August 21, 2025 | globenewswire.comAdvanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®August 21, 2025 | globenewswire.comAlvotech (NASDAQ:ALVO) Trading Up 7.1% - Should You Buy?August 20, 2025 | marketbeat.comAlvotech Appoints Patrik Ling as VP Investor Relations ScandinaviaAugust 20, 2025 | quiverquant.comQAlvotech appoints Patrik Ling as VP of Investor Relations ScandinaviaAugust 20, 2025 | globenewswire.comAlvotech (NASDAQ:ALVO) Short Interest Down 34.3% in JulyAugust 20, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Announces Earnings Results, Beats Estimates By $0.40 EPSAugust 16, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Sees Strong Trading Volume - What's Next?August 16, 2025 | marketbeat.comAlvotech Second Quarter 2025 Earnings: Beats ExpectationsAugust 16, 2025 | finance.yahoo.comAlvotech (NASDAQ:ALVO) Shares Gap Up - Time to Buy?August 15, 2025 | marketbeat.comAlvotech (ALVO) Q2 2025 Earnings Call Highlights: Robust Product Revenue Growth Amid Licensing ...August 15, 2025 | gurufocus.comQ2 2025 Alvotech SA Earnings Call TranscriptAugust 14, 2025 | gurufocus.com Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALVO Media Mentions By Week ALVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALVO News Sentiment▼0.550.54▲Average Medical News Sentiment ALVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALVO Articles This Week▼26▲ALVO Articles Average Week Get the Latest News and Ratings for ALVO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alvotech and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies QGEN News Today ELAN News Today BBIO News Today MRNA News Today VRNA News Today RVMD News Today GRFS News Today RYTM News Today RNA News Today ABVX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALVO) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
